Summary of CD34+ enrichment, CFU transduction efficiency, cell expansion, and engraftment kinetics of animals
Cytokine regimen . | Vector . | CD34+ enrichment* . | Transduction efficiency† . | Initial no.of cells . | No. of cells at the end of culture . | Exp‡ . | No. of infused cells/kg . | Eng1-153 (d) . | F/U1-155 (mo) . |
---|---|---|---|---|---|---|---|---|---|
Animal RQ2314 | 7 | 18 | |||||||
G-CSF | G1Na | 100 | 89% (25 of 28) | 1.4 × 107 | 2.6 × 107 | 1.8 | 6.2 × 106 | ||
G-CSF+SCF | LNL6 | 151 | 96% (27 of 28) | 2.1 × 107 | 2.6 × 108 | 12.4 | 6.2 × 107 | ||
Animal RQ2284 | 9 | 15 | |||||||
G-CSF+SCF | G1Na | 73 | 100% (16 of 16) | 3.0 × 107 | 3.5 × 107 | 1.2 | 7.9 × 106 | ||
G-CSF | LNL6 | 93 | 90% (27 of 30) | 2.2 × 107 | 2.2 × 107 | 1.0 | 4.8 × 106 | ||
Animal RQ2237 | 7 | 12 | |||||||
G-CSF | LNL6 | 113 | 100% (32 of 32) | 1.9 × 107 | 2.4 × 107 | 1.3 | 4.9 × 106 | ||
G-CSF+SCF | G1Na | 95 | 100% (32 of 32) | 4.5 × 107 | 1.1 × 108 | 2.5 | 2.2 × 107 | ||
Animal RQ2277 | 7 | 12 | |||||||
G-CSF+SCF | G1Na | 155 | 100% (32 of 32) | 4.0 × 107 | 2.1 × 108 | 5.2 | 5.0 × 107 | ||
G-CSF+Flt3-L | LNL6 | 95 | 100% (32 of 32) | 1.6 × 107 | 3.1 × 107 | 1.9 | 7.3 × 106 | ||
Animal RQ2265 | 14 | 12 | |||||||
G-CSF+Flt3-L | G1Na | 127 | 100% (32 of 32) | 2.9 × 107 | 4.6 × 107 | 1.6 | 1.0 × 107 | ||
G-CSF+SCF | LNL6 | 72 | 100% (32 of 32) | 3.9 × 107 | 9.2 × 107 | 2.3 | 2.1 × 107 |
Cytokine regimen . | Vector . | CD34+ enrichment* . | Transduction efficiency† . | Initial no.of cells . | No. of cells at the end of culture . | Exp‡ . | No. of infused cells/kg . | Eng1-153 (d) . | F/U1-155 (mo) . |
---|---|---|---|---|---|---|---|---|---|
Animal RQ2314 | 7 | 18 | |||||||
G-CSF | G1Na | 100 | 89% (25 of 28) | 1.4 × 107 | 2.6 × 107 | 1.8 | 6.2 × 106 | ||
G-CSF+SCF | LNL6 | 151 | 96% (27 of 28) | 2.1 × 107 | 2.6 × 108 | 12.4 | 6.2 × 107 | ||
Animal RQ2284 | 9 | 15 | |||||||
G-CSF+SCF | G1Na | 73 | 100% (16 of 16) | 3.0 × 107 | 3.5 × 107 | 1.2 | 7.9 × 106 | ||
G-CSF | LNL6 | 93 | 90% (27 of 30) | 2.2 × 107 | 2.2 × 107 | 1.0 | 4.8 × 106 | ||
Animal RQ2237 | 7 | 12 | |||||||
G-CSF | LNL6 | 113 | 100% (32 of 32) | 1.9 × 107 | 2.4 × 107 | 1.3 | 4.9 × 106 | ||
G-CSF+SCF | G1Na | 95 | 100% (32 of 32) | 4.5 × 107 | 1.1 × 108 | 2.5 | 2.2 × 107 | ||
Animal RQ2277 | 7 | 12 | |||||||
G-CSF+SCF | G1Na | 155 | 100% (32 of 32) | 4.0 × 107 | 2.1 × 108 | 5.2 | 5.0 × 107 | ||
G-CSF+Flt3-L | LNL6 | 95 | 100% (32 of 32) | 1.6 × 107 | 3.1 × 107 | 1.9 | 7.3 × 106 | ||
Animal RQ2265 | 14 | 12 | |||||||
G-CSF+Flt3-L | G1Na | 127 | 100% (32 of 32) | 2.9 × 107 | 4.6 × 107 | 1.6 | 1.0 × 107 | ||
G-CSF+SCF | LNL6 | 72 | 100% (32 of 32) | 3.9 × 107 | 9.2 × 107 | 2.3 | 2.1 × 107 |
Degree of progenitor cell enrichment by CD34 selection was calculated by enumerating total CFUs before and after column purification.
Transduction efficiency calculated by the percentage ofβ-actin-positive colonies that were also neopositive at the end of transduction, as determined by PCR of individual colonies.
Expansion: ratio of the number of cells at the end of 4 days of transduction (number of infused cells) to the number of cells plated on the first day.
Engraftment: days to reach absolute neutrophil count greater than 500/μL.
Follow-up: duration (months) of follow-up after transplantation.